CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.

New Award for Iridium Edge Solar Trackers to Support the Monitoring and Management of High-Value Assets Globally Deployed in Peacekeeping Missions and Field Operations COCONUT GROVE, Fla. , Feb. 12, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL) (NASDAQ: NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that its subsidiary, Global Telesat Communications Ltd ("GTC") has been awarded a new satellite-based asset tracking services contract from a global humanitarian aid customer (the "Customer") following a public tender.

Zelle crossed $1 trillion in total volumes last year, which it said was the most ever for a peer-to-peer platform. The payments network said its user base jumped 12% to 151 million accounts in 2024, and that the total dollars sent on the platform jumped 27% from the year earlier.

Highlights Unanimous Support of Barington's Director Nominees by Leading Proxy Advisory Firms ISS, Glass Lewis and Egan-Jones Believes Matthews' Poor Fiscal 2025 First Quarter Earnings Results Further Demonstrates Management's Pattern of False Hope and Empty Promises Barington's Nominees Bring the Skills, Experience and Fresh Perspectives Required to Help Drive Meaningful Change and Long-Term Value Creation at Matthews NEW YORK , Feb. 12, 2025 /PRNewswire/ -- Barington Capital Group, L.P. ("Barington Capital"), a fundamental, value-oriented activist investor that, together with the other participants in its solicitation (collectively "Barington" or "we"), beneficially owns approximately 2.1% of the outstanding shares of common stock …

BROOKFIELD, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the first quarter of fiscal 2025 on Wednesday, February 26, 2025, before the market opens.

PHILADELPHIA, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI), a global, market-leading provider of environmental solutions for industrial and specialty waste streams, today announced that Company management will be participating in the following upcoming investor conferences: J.P. Morgan 2025 Global Leveraged Finance Conference (Miami Beach, FL)Tuesday, February 25, 2025 BofA Securities 2025 Global Agriculture and Materials Conference (Ft.

IonQ (IONQ -8.21%) has captured the attention of investors looking to play the long game in quantum computing. This nascent market, which is emerging as tech companies invest in entirely new ways of developing computer systems, has a lot of potential to grow.

WEST PALM BEACH, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Advanced Flower Capital Inc. (f/k/a AFC Gamma, Inc.) (Nasdaq: AFCG) (“AFC”) today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, March 13, 2025 before market open. Management will review AFC's financial results at 10:00 am ET via webcast available on the Investor Relations website at investors.advancedflowercapital.com. Participants are also invited to access the conference call by registering in advance at this link. A replay will be available one hour after the event.

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanced melanoma is enrolling Enrolled first patients in trials evaluating RP2 for the treatment of metastatic uveal melanoma and hepatocellular carcinoma WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and …

SAN JACINTO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) announces the grand opening of Esplanade, a brand-new community in the rapidly expanding city of San Jacinto, California.

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leading high-growth platform of better-for-you beverage brands, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, February 26, 2025 before market open. The Company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day.

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024.

SINGAPORE, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, announced today that its Board of Directors (the “Board”) has called for an EGM for shareholders to authorize the Board to carry out a share buyback of up to 20% of the issued share capital of the Company, and to approve the creation of a new class of ordinary shares and preferred shares. In light of the Company's current share price below the exercise price of its previously announced rights offering, the Board has also voted …

The Fast Track designation accelerates troculeucel's path to U.S. FDA submission for the treatment of patients with moderate Alzheimer's disease. NKGen will benefit from increased FDA interactions, enhanced visibility and potential eligibility for Accelerated Approval, Priority Review, and Rolling Review of the regulatory dossier, with a faster path to market for troculeucel.

ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017.

The Only Privacy-First, Ethically Designed AI Built Specifically for Advertising with Real-Time, Cookie-Free Audiences Models The Only Privacy-First, Ethically Designed AI Built Specifically for Advertising with Real-Time, Cookie-Free Audiences Models

CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.

Transaction to Further Accelerate Bold's Growth Amid Increasing Demand for U.S. Natural Gas and Required Treatment Solutions Transaction to Further Accelerate Bold's Growth Amid Increasing Demand for U.S. Natural Gas and Required Treatment Solutions

WILMINGTON, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from February 14, 2025 for an additional month, to March 14, 2025.

PLANTATION, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Alliance Entertainment Holding Corporation (Nasdaq: AENT) is thrilled to announce the launch of its latest line of Handmade by Robots™ collectible figures, which debuted in select Walmart stores nationwide and on Walmart.com on February 7.